Histone deacetylase 6 (HDAC6) is a unique cytoplasmic deacetylase that regulates various important biological processes by preventing protein aggregation and deacetylating different non-histone substrates including tubulin, heat shock protein 90, cortactin, retinoic acid inducible gene I and b-catenin. Growing evidence has indicated a dual role for HDAC6 in viral infection and pathogenesis: HDAC6 may represent a host defence mechanism against viral infection by modulating microtubule acetylation, triggering antiviral immune response and stimulating protective autophagy, or it may be hijacked by the virus to enhance proinflammatory response. In this review, we will highlight current data illustrating the complexity and importance of HDAC6 in viral pathogenesis. We will summarize the structure and functional specificity of HDAC6, and its deacetylaseand ubiquitin-dependent activity in key cellular events in response to virus infection. We will also discuss how HDAC6 exerts its direct or indirect histone modification ability in viral lytic-latency switch.
INTRODUCTION
Post-translational modifications (PTMs) modulate protein function in various cellular processes, which are utilized by pathogens, such as viruses, to favour their infection and pathogenesis [1, 2] . The acetylation of lysine belongs to one of the PTMs that influence several critical events of virus life cycle including chromatin remodelling, gene expression, protein stability, intracellular transport and viral lyticlatency switch. Histone acetyltransferases and histone deacetylases (HDACs) are versatile enzymes responsible for catalysing the acetylation and deacetylation of lysine, respectively. The HDAC6 is identified as the first cytoplasmic HDAC that deacetylates several non-histone substrates, such as tubulin, heat shock protein 90 (Hsp90), retinoic acid inducible gene I (RIG-I) and cortactin, extending the way that acetylation is not an exclusive modification of nuclear proteins [3] . HDAC6, in particular, has distinct structure features and unique cytoplasmic functions in the regulation of cytoskeleton, cell migration, cell reprogramming and pluripotency [4, 5] . Upregulation or activation of HDAC6 has also been implicated in tumorigenesis, neurodegenerative diseases and inflammatory disorders [6, 7] , implying HDAC6 is a potential therapeutic target for pharmacological intervention strategy. While the list of cytoplasmic acetylated proteins controlled by HDAC6 is rapidly growing, the function of HDAC6 in viral infection is still poorly understood. It has become increasingly evident that HDAC6 has both proviral and antiviral effects. HDAC6 can inhibit infection of both RNA and DNA virus by modulating microtubule (MT) cytoskeleton and stimulating selective autophagy, and restrict viral diffusion by triggering antiviral immune response. However, RNA viruses can also utilize HDAC6-mediated aggresome pathway or proinflammatory response to facilitate viral pathogenesis. This review will focus on current studies of the controversial role of HDAC6 in viral infection to figure out whether HDAC6 serves as cellular defence to inhibit viral infection or mediates virus-induced pathogenesis, aiming to highlight HDAC6 as an attractive therapeutic target in infectious diseases.
HDAC6: WHAT MAKES IT DIFFERENT FROM THE OTHER HDACS?
To date, 18 mammalian HDACs have been identified, which are grouped into four classes based on their homology to yeast HDACs [8] [9] [10] . Class I HDACs are orthologues of yeast Rpd3 (reduced potassium dependency-3) and include HDAC1, HDAC2, HDAC3 and HDAC8. Class II members are HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10, which are related to yeast Hda1 and further divided into class IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and class IIb (HDAC6 and HDAC10) according to their sequence homology and domain organization. HDAC11 shares conserved residues in its catalytic core region with HDACs from classes I and II, and represents class IV HDACs due to its distinct structure. Class I, II and IV HDACs are zinc-dependent deacetylases. In contrast, class III HDACs, comprising the Sir2-like deacetylases silent information regulator (Sirt1, Sirt2, Sirt3, Sirt4, Sirt5, Sirt6 and Sirt7), require the presence of the metabolic cofactor NAD + for deacetylation and are generally not inhibited by compounds that inhibit zinc-dependent deacetylases [11] .
HDAC6 STRUCTURAL SPECIFICITY
Among these HDACs, HDAC6 is the only cytoplasmic deacetylase that possesses two catalytic deacetylase domains (DD1 and DD2) and a C-terminal zinc finger ubiquitinbinding domain (BUZ) (Fig. 1 ). These features make HDAC6 unique among all HDAC enzymes, allowing the identification of HDAC6 orthologues in other species, such as Drosophila melanogaster, Caenorhabditis elegans and other invertebrates [12] . It is also important to highlight the presence of a Ser-Glu-containing tetradecapeptide (SE14) repeat domain responsible for the intracellular retention and tau interaction of human HDAC6, which has not so far been found in other HDAC6 orthologues [13] . Besides, a conserved nuclear export signal (NES) at the N terminus plays an essential role in the cytoplasmic/nuclear shuttling process.
Up to now, the most common conclusion to be drawn from several contradictory studies is that the second domain, DD2, has a detrimental role in the total HDAC6 tubulin deacetylase activity [14] [15] [16] . Besides, the specific role of the conserved two catalytic domains DD1 and DD2 within the entire deacetylase activity of HDAC6 has been confirmed by the recently resolved crystal structure of DD1 and DD2 from zebrafish HDAC6 and DD2 from Homo sapiens [17, 18] . DD1 has a weak but measurable enzymatic activity and is highly specific for substrates bearing C-terminal acetyl lysine residues, whereas DD2 exhibits broad substrate specificity. More importantly, DD2 deacetylates a-tubulin Lys 40 in the lumen of MTs, and its preferred substrate is unpolymerized tubulin [18] . In addition, helix H25 and the loop H20-H21 containing a flexible tryptophan residue (Trp 459 ) of DD2 are critical for the deacetylation of tubulin. Another remarkable structural domain of HDAC6 is the presence of a conserved cysteine-and histidine-rich domain in BUZ, which specifically recognizes unanchored mono-and polyubiquitin chains. This domain exhibits a similar structure characteristic to other human zinc finger domains recognizing ubiquitin [19] . This domain enables HDAC6 to bind and mediate the transport of ubiquitinated and mainly misfolded proteins along MT tracks to pericentriolar structures, to facilitate the formation of aggresomes, a cellular protective response to the accumulation of cytotoxic protein aggregates scattered in the cytoplasm, and finally to activate autophagy for clearance [20, 21] .
HDAC6 FUNCTIONAL SPECIFICITY
Unlike other HDACs that localize predominantly in the nucleus, HDAC6 is exclusively found in the cytoplasm owing to the NES and SE14 domain, indicating that HDAC6 has functions that are unrelated to histone modification. Indeed, HDAC6 regulates many important biological processes, including cell migration, immune response, cell proliferation and differentiation, and the degradation of misfolded proteins through both deacetylase-and ubiquitin-dependent mechanisms (Fig. 1) [5, 7] .
Deacetylase-dependent functions
In the cells, HDAC6 mediates diverse cellular functions by removing the acetyl groups from multiple cytoplasmic substrates rather than histones ( Table 1 ). The substrate scope of HDAC6 has been increasingly enlarged, and so far, the best-characterized interaction with a substrate is with atubulin [22, 23] . Deacetylation of a-tubulin at Lys 40 catalysed by HDAC6 regulates MT stability and MT-dependent intracellular trafficking, chemotaxis and immune synapse formation. Apart from a-tubulin, HDAC6 can also regulate the activity of cortactin, an F-actin binding protein, and thus modulate actin reorganization and link actin dynamics to cell motility [24] . Besides, recent findings have revealed that septins, cytoskeletal guanosine triphosphatase proteins that participate in the establishment and maintenance of asymmetry actin reorganization during cell morphogenesis, provide a physical scaffold for HDAC6 to achieve efficient MT deacetylation [25] . In this way, HDAC6 couples and allows the coordination of the two ubiquitous cytoskeletal systems. Another important HDAC6 substrate is chaperone Hsp90 [26] . HDAC6-dependent Hsp90 deacetylation may affect the instability of some of its client proteins with critical roles in cell growth and survival [27] . Furthermore, proteomic identification and functional characterization of other substrates, such as b-catenin, Hsc70 and survivin, may provide clues about the role of HDAC6 in the mechanisms of pathology and physiology [7, 28] .
Ubiquitin-dependent functions
Through its ubiquitin-binding activity, HDAC6 plays a vital role in the formation of aggresomes, which store potentially toxic misfolded proteins and promote their clearance by autophagy when the capacity of the primary 'quality control' mechanism -the proteasomes -is disrupted or overloaded. HDAC6 can bind to ubiquitinated proteins and dynein motors, stimulate MT-dependent and dynein-mediated transport, and thereby promote aggresome formation [20, 21] . On the other hand, HDAC6 regulates the fusion of autophagosome and lysosome through both catalytic deacetylase and ubiquitin-binding activities, resulting in the autophagic degradation of incorporated substrates [21] . Importantly, HDAC6 controls the stability of ubiquitinated proteins through the association with p97/valosin-containing protein (p97/VCP), a chaperone-like AAA adenosine triphosphatase involved in protein degradation via the ubiquitin-proteasome system [29, 30] . More interestingly, p97/VCP is able to dissociate the HDAC6-ubiquitin complexes and therefore allows their further processing [31, 32] . It seems that the equilibrium of cellular concentration of HDAC6 and p97/ VCP determines whether polyubiquitinated proteins are targeted for proteasomal degradation, deubiquitinated and functionally recycled by p97/VCP, or targeted for sequestration into the aggresome and autophagy-dependent degradation by HDAC6.
Together, recent studies have established HDAC6 as a major cytoplasmic regulator with properties that are not shared by other HDACs, which is consistent with its unique domain organization.
HDAC6 ACTIVITY REGULATION
Multiple studies on the regulation of HDAC6 activity have shown that PTMs, including phosphorylation and acetylation, play a critical role in both cytoplasmic and nuclear functions of HDAC6 (Fig. 2) . Phosphorylation has been extensively demonstrated to enhance the activity of HDAC6. For example, phosphorylation at position 22 (Ser
22
) by glycogen synthase kinase 3 (GSK3b) [33] and at position 1035 (Ser 1035 ) by epidermal growth factor receptor (EGFR)-RAS-RAF-mitogen-activated protein kinase (MAPK) kinase (MEK)-extracellular signal-regulated kinase (ERK) signalling axis [34] significantly increased the HDAC6 tubulin deacetylase activity (Fig. 2a) to regulate cell motility in vitro, whereas Ser 1035 is phosphorylated in response to the activation of the EGFR-RAS-RAF-MEK-ERK signalling pathway in vivo [34] . Similarly, other kinases, such as G protein-coupled receptor kinase 2 Suppression of growth and survival signalling [162] (GRK2) [35, 36] , aurora A [37] and protein kinase C isoform z (PKCz) [38] , are also found to phosphorylate and increase HDAC6 tubulin deacetylase activity at positions that remain undefined. Another example of enhanced HDAC6 activity by phosphorylation is provided by protein kinase CK2 (formerly casein kinase II), which phosphorylates HDAC6 at position 458 (Ser 458 ) to enhance the formation and clearance of aggresomes [39] . Furthermore, upon Sendai virus infection, HDAC6 is phosphorylated and activated by PKCa, leading to the deacetylation and nuclear translocation of b-catenin and subsequently the induction of antiviral immune response [40] .
HDAC6 itself is also regulated by acetylation. Acetylation impairs HDAC6's activity against a-tubulin and transcriptional regulation [41, 42] . Early studies have shown that acetyltransferase p300 acetylates HDAC6 at 16 lysine residues, leading to the inhibition of tubulin deacetylation and the suppression of Sp1 transcriptional activity (Fig. 2b) . Besides, as the result of acetylation, HDAC6 is retained in the cytoplasm through the separation from the nuclear import protein importin-a, a process accompanying impaired histone deacetylation [42] . It will be interesting to test whether HDAC6 itself or other HDACs can deacetylate HDAC6. In addition to PTMs, it is also worthy of note that several regulators directly interact with HDAC6 to inhibit its deacetylase activity (Fig. 2c) . A particularly well-studied example is the action of tubulin polymerization-promoting protein-1 (TPPP1/p25) [43] [44] [45] . TPPP1 regulates MT acetylation and b-catenin expression by binding to HDAC6 and inhibiting its activity [44, 45] . Overexpression of TPPP1 in cells promotes MT polymerization and an increase in MT acetylation, whereas introduction of TPPP1 RNAi reduces MT acetylation [43] . Phosphorylation of TPPP1 by Rho-associated coiled-coil kinase (ROCK) and cyclin-dependent kinase 1 (CDK1) impairs the interaction between TPPP1 and HDAC6, which, in turn, results in increased HDAC6 activity followed by a decrease in cell motility and an increase in cell proliferation, respectively [46, 47] . Moreover, a broad spectrum of regulators, which directly interact with and inhibit HDAC6 tubulin deacetylase activity or aggresome formation ability, has been well documented, including paxillin [48] , CYLD [49, 50] , dysferlin [51] , Mdp3 [52] , p62 [53] and RanBPM [54] .
Furthermore, RNA silencing is an important regulatory mechanism, and several microRNAs have been shown to regulate HDAC6 expression and function (Fig. 2d) . For instance, hypoxia-responsive miR-26a directly targets the 3¢ UTR of the HDAC6 gene and suppresses HDAC6 expression, leading to the acetylation of histones and finally embryonic stem cell differentiation [55] . Other than miR-26, the activity or expression of HDAC6 is also downregulated by miR-433, miR-221, miR-22 and miR-548m, which, in turn, causes tumour cell growth and metastasis [56] [57] [58] [59] [60] .
HDAC6 ACTS AS CELLULAR DEFENCE AGAINST VIRAL INFECTIONS
Due to the participation of HDAC6 in a wide range of important cellular processes that are essential for virus infection and replication, it is easy to envision that HDAC6 may play an important role during virus infection. In fact, recently published studies have shed light on the antiviral function of HDAC6.
Modulating MT to inhibit viral infection
The reorganization of cell cytoskeleton, including microfilaments and MTs, affects every stage of virus infection from entry to egress [61, 62] . MTs are highly dynamic polymers of a/b-tubulin heterodimers that provide a conduit for trafficking large macromolecules through the cell via the MT motors dynein and kinesin, and play central roles in cell division and spatial organization of the cell cytoplasm. It is conceivable that viruses have evolved mechanisms to hijack the MT transport system for intracellular transportation of virion/viral genomic material to the sites of replication, assembly and egress. For instance, the human immunodeficiency virus 1 (HIV-1) capsid protein p24 interacts with dynein and facilitates trafficking movement of HIV-1 capsids to the perinuclear region or MT-organizing centre (MTOC) [63] . Decreasing MT stability by overexpression of the ezrin-radixinmoesin family members, such as ezrin and moesin, significantly reduces HIV-1 infection at a step prior to reverse transcription [64] .
The acetylation of K40 on a-tubulin, a hallmark of stable MT, is conceived as a key regulatory mechanism promoting MT-based transport, compartmentalization of subcellular organelles and signalling pathways [65] . Moreover, several studies have demonstrated that tubulin acetylation is involved in every stage of virus infection, from entry to assembly and release [66] [67] [68] . For example, infection with influenza A virus (IAV) induces acetylation of a-tubulin in epithelial cells, which, in turn, increases the release of virions from infected cells [68] . However, the detailed mechanism of tubulin acetylation, regulated or not by HDAC6 in virus infection, remains to be determined.
Fusion and entry
Short cortical MTs are directly involved in controlling membrane dynamics, such as actin-dependent ruffle formation, a process that is required for virus-cell fusion and viral penetration [22, 69] . HDAC6 deacetylase activity controls the association between the plasma membrane and acetylated a-tubulin and thereby regulates the dynamic tension of the plasma membrane to affect virus entry. For example, overexpression of active HDAC6 has been shown to markedly prevent HIV-1 envelope-dependent cell fusion and infection by suppressing the acetylation of a-tubulin [70] . In contrast, knockdown of HDAC6 expression or inhibition of its tubulin deacetylase activity strongly enhances virus-cell fusion, HIV-1 infection and syncytia formation. Similarly, overexpression of RhoV14, a constitutively active form of RhoA that activates HDAC6 through mDia2, results in a significant reduction of acetylated tubulin and reduced virus-cell fusion [71] . In this respect, the fusion step acts as the main target for inhibition of infection, in which HDAC6 functions as a restriction factor by modulating the tubulin acetylation and cytoskeletal reorganization. Another conceivable mechanism by which HDAC6 regulates HIVinduced cell fusion and infection is that HDAC6 may regulate actin reorganization to inhibit viral entry through receptor-mediated endocytosis or pH-dependent fusion between HIV-1 and plasma membrane. Cortical actin located immediately beneath the plasma membrane is the first obstacle encountered by the viruses upon infection, and reorganization of the cellular actin cytoskeleton significantly affects virus entry [72] . There is increasing evidence showing the connection between actin regulation and HDAC6 [73, 74] , and cortactin, an important regulator of actin assembly and disassembly, can also be tightly controlled by HDAC6 [24] . Furthermore, the antiviral effect of HDAC6 on virus entry and infection has been examined in vivo, which shows that HDAC6 overexpression significantly enhances resistance to avian H5N1 virus infection and extends the survival rate [75] .
Post-entry and nuclear targeting
Increasing studies have shown that a-tubulin acetylation is utilized by many viruses to facilitate intracellular transportation of virions or viral genomic material to sites of replication [76, 77] . For example, it was reported that HIV-1 intracellular trafficking requires the formation of acetylated and detyrosinated stable MT tracts [78] . The end-binding protein EB1 mediates the virus-induced tubulin acetylation, and HIV-1 matrix protein targets the EB1-binding protein Kif4 to induce MT stabilization. It is tempting to speculate that inhibition of cytoplasmic HDAC6 further stabilizes these stable MT networks and facilitates HIV-1 reverse transcription and transport to the nucleus. Indeed, inhibition of HDAC6-mediated a-tubulin deacetylation by HDAC6-specific inhibitor tubacin enhances HIV-1 infection [63] . Alternatively, HDAC6 inhibition also increases the susceptibility of uninfected CD4 + T cells to HIV-1 by accelerating the kinetics and efficiency of post-entry viral events, including reverse transcription and integration [79] . In the case of circovirus infection, it was found that circovirus capsid subunit enhances tubulin acetylation and directly interacts with the intermediate chain 1 of dynein for retrograde transport. Consequently, destabilization of dynamic MTs by HDAC6-mediated deacetylation impairs MT-dependent nuclear targeting of circovirus [80] .
Replication
Viral replication often occurs in specific regions of the nucleus or the cytosol, and the host's replication apparatus is modified to suit a virus' needs. Tubulin acetylation is such a modification that is involved in the replication process of several viruses, including herpes simplex virus 1 (HSV-1) [81] , mouse norovirus 1 [82] and adenovirus [83] . Besides, tubulin acetylation is supposed to guide and accelerate the nuclear trafficking of post-entry viruses, and inhibition of HDAC6 by its specific inhibitors could apparently improve the replication efficiency of oncolytic viruses [84, 85] . In addition, HDAC6 is capable of regulating the transactivation activity of Tat, a transactivator of transcription protein essential for HIV-1 transcription and replication [86] . HDAC6 can bind and deacetylate Tat at Lys 28 in an MTdependent manner. For this reason, adding the MTdepolymerizing agent nocodazole or the HDAC6 inhibitor tubacin significantly increases Tat transactivation activity. Likewise, modulation of the transcriptional activity of transactivator Tat by HDAC6 is linked to increased gene expression of human T-lymphotropic virus type 1 (HTLV-1) [87] . Beyond the histone deacetylation activity and innate antiviral immunity, it will be interesting to investigate the role of HDAC6 in replication of other virus through its tubulin modulatory effect.
Assembly and egress
Constituents of viral mature particles utilize the exocytic vesicular transport pathway for targeting to the assembly site and the plasma membrane for release, and such vesicular trafficking is mediated by MTs [88, 89] . Thus, by regulating MT dynamic, HDAC6 may impair viral assembly and release. In fact, IAV ribonucleoprotein complex is colocalized with acetylated MTs and HDAC6 exerts its antiinfluenza virus activity by negatively regulating the trafficking of viral components to the assembly site via its substrate, acetylated MTs. As a result, inhibiting the deacetylase activity of HDAC6 by tubacin increases the release of IAV progeny in a dose-dependent manner [90] . Mechanistically, a recent report has demonstrated that the caspase-3 cleavage motif DMAD-S exists at the C terminus of HDAC6 between the SE14 domain and BUZ domain, and such cleavage removes most of the BUZ domain from HDAC6 in influenza virus-infected cells. IAV may possibly downregulate the deacetylase activity of HDAC6 through the induction of caspase-3-mediated cleavage of HDAC6 polypeptide [91] . However, further work is required to determine whether this cleavage by IAV affects tubulin acetylation or viral assembly and budding. Moreover, cortactin, another HDAC6 substrate, is downregulated through caspase-3-mediated cleavage and lysosome-associated degradation [92] . Cortactin may promote IAV entry by stabilizing the filamentous actin required for efficient endocytosis of incoming virions, whereas the stabilized actin network represents a barrier for the release of budded IAV progeny. Therefore, downregulation of cortactin can be a potential strategy usurped by IAV for viral release. In addition, HDAC6 may regulate actin remodelling under the plasma membrane to restrict viral assembly and budding [93, 94] , when considering that actin cytoskeleton has been shown to associate with IAV infection [95] [96] [97] .
In summary, these data strongly implicate HDAC6 as an antiviral defence factor partly through modulating tubulin acetylation and MT dynamics. Except for acetylated atubulin, Hsp90, cortactin and b-catenin can be the other potential effectors of the antiviral function of HDAC6. For instance, Hsp90 has been widely shown to regulate viral nuclear trafficking and replication [98] . It is therefore reasonable to propose that the antiviral activity of HDAC6 may be through the modulation of Hsp90 chaperone function [99] .
Controlling antiviral immune responses
In addition to controlling the spatial and local reorganization of MT upon viral entry or intracellular trafficking, HDAC6 links the MT cytoskeleton with immune synapse organization and induces the immune defence of host cells to restrict viral spread and pathogenesis through its deacetylase activity [100] . Following virus infection, a variety of membrane-bound or cytoplasmic sensors, including Tolllike receptors, RIG-I-like receptors and nucleotide-binding and oligomerization domain-like receptors, recognize viral RNA or DNA and subsequently initiate signals leading to the induction of type 1 interferon (IFN) transcription via transcriptional factors such as interferon regulatory factor 3 (IRF) and nuclear factor kB (NF-kB) [101] . Like other transcriptional signalling pathways, reversible protein acetylation is also involved in innate antiviral response [102] . More specifically, HDAC6 functions as a coactivator of virus-induced IRF-3-dependent transcription. Silencing or inhibition of HDAC6 by the pan-HDAC inhibitor trichostatin A (TSA) significantly reduces IRF-3-mediated IFN-b expression [103] . Recently, studies from different groups have clearly elucidated the upstream signalling pathway leading to HDAC6 activation and its downstream target in antiviral signalling (Fig. 3a) . Upon Sendai virus infection, HDAC6 is activated by PKCa-mediated phosphorylation, leading to the deacetylation of b-catenin and finally IRF-3-mediated gene induction [40] . Along with HDAC6-mediated b-catenin deacetylation, PKCb-mediated phosphorylation ofCBP (cyclic adenosine monophosphate response element-binding protein-binding protein) is also required for IRF-3's transcriptional activity [104] . b-Catenin bridges activated nuclear IRF-3 and CBP to form a stable transcription initiation complex at the target gene promoters. Apart from IRF-3 downstream activation, HDAC6 also participates in RIG-Imediated antiviral sensing pathway. RIG-I is a key cytosolic sensor that recognizes and binds to 5¢-triphosphate dsRNA of RNA viruses. In resting cells, the K858 and K909 residue of RIG-I are acetylated, which reduce its translocation to the intracellular membranes and its 5¢-triphosphate dsRNA binding ability [105, 106] . Upon virus infection, HDAC6-mediated deacetylation of RIG-I is critical for viral RNA detection [105, 106] . HDAC6 transiently binds to RIG-I and removes the Lys 909 acetylation in the presence of viral RNAs, promoting RIG-I oligomerization and sensing of viral RNAs, leading to the activation of downstream signalling, Mitochondrial Antiviral Signaling Protein (MAVS)-IRF-3-NF-kB and finally the expression of IFN-b and a variety of antiviral and immunomodulatory genes (Fig. 3b) . Consequently, like IRF-3 -/-mice, HDAC6 -/-mice are highly susceptible to RNA virus infection, highlighting the importance of HDAC6 in triggering innate antiviral immune signalling [104] [105] [106] . In the future, it will also be interesting to examine the role of HDAC6 in the antiviral immune response against DNA virus infection.
In addition, autophagy emerges as a component of innate immunity as it can destroy infectious viruses or viral components essential for viral replication or assembly, a process referred to as virophagy, linking virus detection to antiviral innate immune signals or participating in the regulation of immune and inflammatory cell response [107, 108] . In this circumstance, HDAC6 facilitates aggresome formation and autophagic degradation for the clearance of intracellular invasive viruses or viral proteins. For example, HDAC6 can antagonize HIV-1 infection by inducing autophagic degradation of the viral infection factor (Vif) [109] . Vif recognizes several cellular antiviral proteins, such as APOBEC3G (A3G), promotes their degradation and therefore eludes their restrictive activities against HIV-1 [110, 111] . In addition, it was shown that HDAC6 interacts with Vif or A3G and competes for Vif-A3G interaction through its BUZ domain, impairs the incorporation of Vif into nascent virions and finally controls HIV-1 infectiveness (Fig. 4) . Additionally, HDAC6 can restrict viral spread by interacting with interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins, targeting them for selective autophagic degradation [112] . Previous work has demonstrated that ISG15 knockout mice are broadly susceptible to RNA and DNA viruses [113] . More detailed study has shown that ISG15 could broadly conjugate IFN-induced ISGs and viral proteins, mediating their degradation during the process of virion egress and release. In this process, HDAC6 promotes the recycling of ISG15, via the direct binding of the C-terminal LRLRGG of ISG15 with the HDAC6 BUZ domain, and links selective autophagy to efficiently remove ubiquitin and ISG15-tagged unwelcomed proteins or pathogens (Fig. 4) .
Besides viral recognition in innate immunity, HDAC6 is also essential for antigen presentation and cytotoxic T lymphocyte (CTL)-mediated lysis of virus-infected cells in adaptive immune response, in which viruses have exploited various strategies to evasive T cell immunity [114] . On one hand, HDAC6 controls the stability of virus-derived peptides, which has great impacts on subsequent epitope presentation at the cell surface by MHC class I molecules and on the recognition and elimination of virus-infected cells by virus-specific CTLs [115] . For instance, the half-life of HIVderived peptides is reduced following HDAC6 depletion or in the presence of the chemical inhibitor TSA, indicating that HDAC6 protects peptides from cytosolic degradation. On the other hand, HDAC6 increases the antiviral function of CD8 + T cell in HTLV-1 infection with unclear mechanism [86] . One possible explanation for HDAC6-enhanced T cell-mediated cytotoxicity is that CTLs are highly motile cells and require a dynamic cytoskeleton to actively approach potential target cells, whereas inhibition of HDAC6 is known to reduce cell migration. A recent study has demonstrated that HDAC6 is an effector of the immune cytotoxic response that acts by affecting the dynamics, transport and secretion of lytic granules by CTLs [116] . Taken together, the works summarized above demonstrate that HDAC6 is an essential component of autophagy-based immune response and an effector of the CTL response to viral infection.
In conclusion, HDAC6 inhibits viral infection either by modulating MT cytoskeleton or by controlling antiviral immune responses. A better understanding of the role of HDAC6 in regulating cytoplasmic proteins and cytoskeletal architecture will provide insight into critical events in the viral life cycle and provide strategies for the development of agents that specifically target viral pathogenesis. As an alternative antiviral approach, those proteins that interact with and inactivate HDAC6 such as TPPP1 may be promising targets, or HDAC6 stimulators may be employed to stimulate the antiviral potential of endogenous HDAC6 to restrict virus infection. In resting cells, K858 and K909 at the C-terminal repressor domain (RD) is acetylated to hold RIG-I in an autorepressed state with limited RNA binding ability. Upon virus infection, HDAC6 is activated to deacetylate RIG-I, leading to RIG-I oligomerization and subsequent antiviral gene expression.
HDAC6 IS EXPLOITED BY VIRUSES
likely that the different effects are related to the specific virus type or different stages of viral life cycle.
HDAC6-MEDIATED AGGRESOME PATHWAY FOR VIRAL UNCOATING
In the aggresome pathway, HDAC6 plays a key role in gathering polyubiquitinated protein aggregates through its BUZ domain, transporting them to aggresomes via MT tracts and activating autophagy for clearance (Fig. 5a ) [20, 21, 117] . Interestingly, increasing evidence suggests that the replication or assembly of many viruses, such as poxviruses, African swine fever virus, iridoviruses and phycodnaviruses, occurs in large insoluble inclusion bodies called 'viral factories', which are generally localized near the MTOC and share several features with pericentriolar aggresomes [118] . Besides, several viruses induce aggresomes and autophagosomes to generate sites of replication or assembly [119, 120] , and viral oncoproteins are recruited to aggresomes by interacting with HDAC6 [121, 122] . Whether the aggresome pathway represents an adaptive niche for virus infection and detailed mechanism needs to be further defined.
Recent work has identified additional cellular function of the HDAC6-mediated aggresome pathway for IAV uncoating and replication after its escape from the endosome during entry into the host cell (Fig. 5a ) [123] . IAV infection is significantly reduced in HDAC6-depleted cells in vitro or in HDAC6 knockout mice due to the impaired uncoating and nuclear import [123] . HDAC6 binds unanchored ubiquitin chains of viral NP and M1 proteins and IAV virions, links them to the aggresome processing machinery such as dynein, myosin 10 and MTs, and transfers opposing physical forces to promote capsid disassembly and uncoating. The BUZ domain is essential for recruitment of HDAC6 to viral fusion sites and for efficient uncoating. However, an alternative interpretation could be that a high amount of virus inoculum used to visualize the IAV uncoating may have led to the recognition of ubiquitin-containing IAV capsids as protein aggregates and their mistargeting to the aggresomes for clearance not uncoating. Besides, it has been shown earlier that, in addition to the BUZ domain, the deacetylase activity of HDAC6 is also required for aggresome formation and disassembly [20, 124] . Banerjee et al. do not support a role for HDAC6 deacetylase activity in IAV capsid uncoating, further supporting the alternative interpretation. Moreover, the BUZ domain of HDAC6 is cleaved in IAV-infected cells mostly at 24 h post-infection [91] , whereas HDAC6 facilitates the influenza virus uncoating nearly before 6 h post-infection. It seems that the BUZ cleavage would affect IAV release, not early events. However, we cannot exclude the possibility that the IAV-infected cells may produce a bystander effect, through which caspase-3 is activated to cleavage HDAC6 in non-infected cells. conclude most of their findings, and the potential caspase-3 cleavage motif DLQD (aa 1128-1131) exists in mouse HDAC6. It will be interesting to test whether mouse HDAC6 is also cleaved during IAV infection. In any case, such difference and the caspase-3-mediated cleavage may affect the conclusion obtained by Banerjee et al. Further work is required to investigate the role of proteasome and Poh1, a deubiquitinating enzyme that cleaves off ubiquitin chains en bloc from substrates targeted to the proteasome and activates HDAC6, to exclude the possibility of proteasome-mediated clearance of IAV. Finally, it will be interesting to investigate whether the HDAC6-mediated aggresome pathway is involved in uncoating other enveloped viruses, including HIV-1 and Ebola virus, since ubiquitin widely exists in their viral mature particles [125] [126] [127] .
Facilitating viral pathogenesis
The extensive inflammatory response upon virus infection may contribute to the development of virus-related disease, which is associated with upregulated expression of proinflammatory mediators, including cytokines, chemokines and adhesion molecules [128] . HDAC6 has been implicated in the regulation of proinflammatory gene [129] . Inhibition of HDAC6 activity significantly suppresses lipopolysaccharideinduced activation of macrophages and production of proinflammatory cytokines [130] . It is thus easy to envision that the immunomodulatory activities of HDAC6 may prompt virusinduced inflammatory responses. For instance, HDAC6 has been shown to regulate MAPK-NF-kB/AP-1 signalling pathways to link the HIV-1 Tat activity to the expression of chemokines CCL2, CXCL8, and CXCL10; adhesion molecules ICAM-1 and VCAM-1; and subsequent adhesion of monocytes to astrocytes (Fig. 5b) . These results highlight HDAC6 as a potential target for the treatment of HIV-1 Tat-associated neurological disorders [131] , and indeed, ITF-2357, a pan-HDAC inhibitor, attenuates virus-induced proinflammatory responses [132] .
In addition, the deacetylase activity of HDAC6 is necessary for hepatitis C virus (HCV) replication, as HDAC6-specific inhibitors, tubastatin A, pyridine hydroxamic acids and benzohydroxamic acids significantly impair HCV replicon propagation [133] [134] [135] [136] . HDAC6 has also been implicated in the establishment of chronic infection of HCV. Miura et al. have demonstrated that chronic HCV infection induces the accumulation of reactive oxygen species and subsequently evokes HDAC activity, which, in turn, deacetylates histones and regulates the location and activities of hypoxiainducible factors, CCAAT/enhancer binding protein a and signal transducers and activators of transcription 3 to suppress the expression of hepcidin, a key negative regulator of iron availability [137] . Sustained low hepcidin expression may contribute to the elevated iron accumulation in the liver and chronic hepatitis. Conversely, the HDAC inhibitor TSA restores hepcidin expression and alleviates iron deposit in HCV-infected liver. Further works are required to elucidate the exact role of HDAC6, as well as other class II HDACs, in HCV pathogenesis.
In summary, the above studies represent a major advance in our understanding of the role of HDAC6 in promoting viral uncoating and proinflammatory response. These new works support exploration of a potential therapeutic role for restricting viral pathogenesis by targeting HDAC6.
HDAC6 CONTROLS VIRAL LYTIC-LATENCY SWITCH
Viral latency is the ability of a virus to lie dormant (latent) within a cell, to evade the host cell's immune response and to establish lifelong infection. Viral latency is associated with transcriptional silencing of the integrated provirus, in which only few viral genes are expressed after viral initial infection. The stimuli that promote the switch between latency and lytic reactivation are poorly characterized, but the maintenance of repressive chromatin and transcription regulation, mainly controlled by histone reverse acetylation, is critical for latency [138] [139] [140] . This raises the possibility that inhibition of HDACs may reactivate latent proviruses. Indeed, HDAC6 inhibitors, as well as other HDACs, are subsequently found to reactivate HIV [141] [142] [143] [144] , EpsteinBarr virus [145] [146] [147] , Kaposi's sarcoma-associated herpesvirus (KSHV) [148, 149] and feline immunodeficiency virus [150] .
HDAC6 may regulate viral latency directly by inducing histone deacetylation and indirectly through non-histone protein modification. For instance, HIV latency arises when the regulatory feedback mechanism driven by the regulatory protein Tat is below threshold levels [151] . HDAC6 deacetylates Lys 28 of Tat in the nucleus and inhibits Tat transcriptional activity by triggering its export to the cytoplasm, thus maintaining HIV latency [86] . In contrast, HDAC6 regulates KSHV reactivation switch through a less clear mechanism [149] . Overexpression of HDAC6 can significantly inhibit KSHV latency-lytic switch mediated by TPA, a widely accepted chemical inducer of KSHV reactivation from latency. Besides, HDAC6 may shuttle from the cytoplasm to the perinucleus and nucleus to repress transcription by recruiting Sp1 and Runx2 to gene promoters [152, 153] , or active RNA polymerase II on the bodies of transcribed genes [154] , both of which are critical for KSHV reactivation. It is hoped that purging viruses, HIV in particular, from the latent reservoir by HDAC6 inhibitors will lead to the killing of the productively infected cells and the blockage of novel infection when combined with other antiviral therapy. Indeed, purging the latent reservoir of HIV-1 in resting CD4 + T cells by HDAC inhibitors is under active clinical investigation [142] .
PERSPECTIVES
HDAC6 plays a key role in many signalling pathways and regulates various important biological phenomena, especially in coordinating cell responses to stressful stimuli, such as virus infection. The involvement of HDAC6 in virus infection has increased, and the diverse range of processes in which HDAC6 is previously unknown to participate gradually emerges. It will be interesting to explore the underlying mechanism by which virus antagonizes HDAC6-mediated restriction. Except for tubulin, further work is also required to investigate the roles of other HDAC6 substrates, such as Hsp90 and RIG-I, in virus infection. Although it is tempting to postulate HDAC6 as a valid target for pharmacological intervention strategies, accumulating evidence suggests that a more complicated scenario and the simple conclusion that HDAC6 stimulators or inhibitors may be employed to stimulate the antiviral potential of endogenous HDAC6 require re-assessment.
According to recent studies, HDAC6 inhibitors only demonstrate potential antiviral activities against HCV infection [133] [134] [135] [136] . However, whether HDAC6 exerts an inhibitory effect on the entry and nuclear trafficking of HCV, like other viruses, remains elusive. Alternatively, HDAC6 inhibitors hold rich promise in improving treatment efficacy of oncolytic virus therapy. Oncolytic viruses are genetically engineered, tumour-targeted viruses (such as oncolytic adenovirus and oncolytic herpesvirus), and their lytic actions against tumour cells rely on efficient entry, replication and intratumoural spread, which may be impeded by several host restriction factors. HDAC6 is such an intrinsic intracellular defence factor of some tumour cells against virotherapy, and inhibition of HDAC6 could thereby improve these critical initial phases of virotherapy. Indeed, inhibition of HDAC6 apparently improves the replication efficiency of oncolytic HSV in cancer cells [84, 85] . Furthermore, HDAC6 inhibitors can purge viruses from the latent reservoir and thereby represent an attractive strategy to kill the productively infected cells and deplete the reservoir of latently infected viruses when combined with antiviral therapy. Nonetheless, the single use of HDAC6 inhibitors in cancer treatment or neurodegenerative disease should be considered more carefully because HDAC6 inhibitors may increase susceptibility to virus infection or reactivate latent viruses. HDAC6 inhibition will destroy the equilibrium between inflammatory microenvironment and immune response, and consequently will promote the development of tumours or neurodegenerative disorders induced by viral infection. Finally, substantial efforts aiming to develop novel HDAC6-selective inhibitors, as well as activators, under active clinical investigation can be anticipated. 
